Comparative Pharmacology
Head-to-head clinical analysis: VENTOLIN versus VENTOLIN HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VENTOLIN versus VENTOLIN HFA.
VENTOLIN vs VENTOLIN HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP, leading to relaxation of bronchial smooth muscle.
2 inhalations (100 mcg/inhalation) via metered-dose inhaler every 4-6 hours as needed for bronchospasm. For nebulization: 2.5 mg (0.5 mL of 0.5% solution) in 2.5 mL sterile normal saline, inhaled via nebulizer 3-4 times daily.
90 mcg (2 inhalations) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
Terminal elimination half-life 3-4 hours (nebulized, oral); 4-6 hours (intravenous); prolonged in renal impairment
3-4 hours for systemically absorbed albuterol; terminal half-life is approximately 3.8 hours. No accumulation with repeated dosing.
Renal (60-70% as unchanged drug and metabolites), biliary/fecal (minor, <10%)
Renal (60-70% as unchanged drug and metabolites, primarily as sulfate conjugate; biliary/fecal: minor, <10%).
Category C
Category C
Short-Acting Beta-2 Agonist
Short-Acting Beta-2 Agonist